KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Capital Leases (2016 - 2017)

Nektar Therapeutics has reported Capital Leases over the past 8 years, most recently at $3.0 million for Q3 2017.

  • Quarterly results put Capital Leases at $3.0 million for Q3 2017, up 39.99% from a year ago — trailing twelve months through Sep 2017 was $3.0 million (up 39.99% YoY), and the annual figure for FY2016 was $2.2 million, up 107.18%.
  • Capital Leases for Q3 2017 was $3.0 million at Nektar Therapeutics, down from $3.8 million in the prior quarter.
  • Over the last five years, Capital Leases for NKTR hit a ceiling of $10.8 million in Q1 2013 and a floor of $1.1 million in Q4 2015.
  • Median Capital Leases over the past 5 years was $5.3 million (2014), compared with a mean of $5.6 million.
  • Biggest five-year swings in Capital Leases: tumbled 75.0% in 2015 and later soared 121.53% in 2016.
  • Nektar Therapeutics' Capital Leases stood at $8.0 million in 2013, then crashed by 48.58% to $4.1 million in 2014, then plummeted by 74.08% to $1.1 million in 2015, then surged by 107.18% to $2.2 million in 2016, then surged by 34.95% to $3.0 million in 2017.
  • The last three reported values for Capital Leases were $3.0 million (Q3 2017), $3.8 million (Q2 2017), and $4.5 million (Q1 2017) per Business Quant data.